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AbsTrACT
Although faecal microbiota transplantation (FMT) has 
a well-established role in the treatment of recurrent 
Clostridioides difficile infection (CDI), its widespread 
dissemination is limited by several obstacles, including 
lack of dedicated centres, difficulties with donor 
recruitment and complexities related to regulation and 
safety monitoring. Given the considerable burden of CDI 
on global healthcare systems, FMT should be widely 
available to most centres.
Stool banks may guarantee reliable, timely and equitable 
access to FMT for patients and a traceable workflow 
that ensures safety and quality of procedures. In this 
consensus project, FMT experts from Europe, North 
America and Australia gathered and released statements 
on the following issues related to the stool banking: 
general principles, objectives and organisation of the 
stool bank; selection and screening of donors; collection, 
preparation and storage of faeces; services and clients; 
registries, monitoring of outcomes and ethical issues; and 
the evolving role of FMT in clinical practice,
Consensus on each statement was achieved through 
a Delphi process and then in a plenary face-to-face 
meeting. For each key issue, the best available evidence 
was assessed, with the aim of providing guidance for 
the development of stool banks in order to promote 
accessibility to FMT in clinical practice.
InTroduCTIon
Faecal microbiota transplantation (FMT) has a 
well-established role in the treatment of recurrent 
Clostridioides difficile infection (CDI).1–13 FMT 
working protocols have undergone considerable 
advancements in recent years, including the use of 
frozen faeces,2 capsules6 and the release of guide-
lines to provide methodological guidance.14–17
Despite these improvements, the dissemination 
of FMT has been limited owing to lack of dedicated 
centres, difficulties with donor recruitment, regu-
latory and safety concerns. Given the increasing 
burden of CDI,18 19 the provision of FMT should be 
widely and rapidly accessible. Moreover, as recently 
highlighted in a warning from the Food and Drug 
Administration (FDA), FMT requires strict quality 
control to prevent harmful consequences.20
Stool banks can provide reliable, timely and equi-
table access to FMT for CDI, and also facilitate a 
standardised, cost-effective and traceable work-
flow that ensures safety and quality of procedures21 
compared with single FMT centres. Stool banks are 
currently unevenly distributed and differ consider-
ably in legislation, organisation and structure.22–24
The aim of this consensus report is to provide 
guidance on the general organisation and the 
criteria required to establish a stool bank.
MeThods
Consensus development process
The consensus process was developed according 
to the following steps: selection of expert panel 
members, identification of key issues and related 
working group (WG), development of statements 
based on best available evidence, achievement of 
consensus through the Delphi technique and a face-
to-face final meeting.
Twenty-nine consensus members, with docu-
mented expertise in the field of FMT and stool 
banking, took part in the expert panel. Based on 
personal expertise, each member was assigned 
to one of six WGs: general principles, objectives 
and organisation of the stool bank; selection and 
screening of donors; collection, preparation and 
storage of faeces; services and clients; registries, 
monitoring of outcomes, and ethical issues; and 
update on FMT in clinical practice. Each WG 
proposed a list of key issues and developed state-
ments related to the assigned topic(s).
For each key issue, the best available evidence 
was obtained through a systematic review of the 
pertinent literature. If the related statements were 
suitable for Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) 
assessment, based on PICO (population, interven-
tion, comparator, outcome) questions, they have 
been graded accordingly.25 26 Otherwise, statements 
were released only as expert opinions.
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The elaborated statements were uploaded to an online voting 
system (http:// armstrong. wharton. upenn. edu/ delphi2/)27 and 
disseminated to the panel. Experts’ responses were collected, 
addressed and shared with the panel after each round. For each 
statement, experts were requested to rate their level of agree-
ment: (1) agree strongly; (2) agree with reservation; (3) unde-
cided; (4) disagree; (5) disagree strongly.
Consensus was achieved if at least 80% of respondents 
expressed a strong agreement or an agreement with reserva-
tion. Statements that did not pass this threshold were revised 
and rated again in further voting rounds, until consensus was 
reached.
Panel experts gathered in Rome on 22 June 2019 for refine-
ment and final approval of the statements.
resulTs
Three rounds of voting were necessary to reach consensus for 
all statements. Respectively, 73% of statements passed the 80% 
agreement threshold after the first round, 90% after the second 
round, and 100% after the third round. Overall, the expert panel 
released 40 statements. Of these, 17 were developed according 
to the GRADE approach, and 23 were based on expert opinion 
(EO). For statements developed through the GRADE approach, 
the certainty of evidence (CoE) and the strength of recommen-
dation (SoR) were indicated.
General principles, objectives and general organisation of the 
stool bank
(1) Statement (EO): Stool banks aim to safely collect, store and 
distribute faeces from screened healthy donors that have been 
processed and stored, in order to treat CDI through FMT. Stool 
banks may also participate in research protocols under strict 
investigative conditions.
Comment: The principal aim of the stool bank is the provision 
of FMT to healthcare centres to treat recurrent or severe CDI in 
a timely, safe and traceable manner. Stool banks would relieve 
hospitals from the administrative burdens of individual FMT 
donor programmes and enhance the standardisation of FMT.28
(2) Statement (EO): Stool banks should guarantee high levels 
of security in the processing of patients’ and donors’ personal 
data, according to national or higher-level regulation.
Comment: Management of records related to all FMT steps 
should be regulated by local health organisations. This should 
ensure that the fundamental right to protection of personal data 
is fully guaranteed, following pertinent national and/or interna-
tional legislation.29 All necessary measures should be taken to 
ensure that the data processed are kept confidential and secure 
and that donors and recipients are not identifiable.
(3) Statement (EO): The director of the stool bank should 
fulfil the following criteria: medical microbiologist or infectious 
disease specialist or gastroenterologist with scientific and clinical 
experience in the field of FMT.
The director should ensure (a) that the stool bank primarily 
functions for the provision of faecal suspensions for the treat-
ment of CDI; (b) that the material used is consistently collected, 
controlled, processed, stored and distributed, pursuant to appli-
cable rules and regulations; (c) donor–recipient traceback; (d) 
participation in research protocols under strict investigative 
conditions.
Comment: The panel suggests that the stool bank director 
should have had specialty training in gastroenterology, micro-
biology or infectious diseases (as CDI is usually managed within 
these specialties) and should have specific expertise in FMT. The 
director should guarantee that the bank provides faecal suspen-
sions in clinical practice only to treat CDI, and that participation 
in research protocols is accepted only for rigorously designed 
and ethically approved studies. Moreover, he/she must ensure 
that the stool bank respects pertinent legislation and that trace-
ability of bank processes is guaranteed.
(4) Statement (EO): The director of the stool bank should 
appoint the members of the scientific committee, who must have 
experience in the field of FMT, for clinical, regulatory and scien-
tific advice. The scientific committee and the director should 
then appoint (a) a responsible physician, who coordinates indi-
vidual requests for access to the bank from accredited healthcare 
facilities; (b) a physician(s), who evaluates, selects and recruits 
stool donors; (c) a microbiologist and/or pharmacist, who coor-
dinates all the processes connected to the processing of faeces 
in the laboratory, up to storage; (d) a biobanking expert, who 
appropriately stores faeces under standardised conditions; (e) a 
director of quality management to ensure compliance with the 
various procedural steps.
Comment: Together, the director and the scientific committee 
should appoint appropriate professional figures to oversee all 
fundamental processes of the stool bank, including the recruit-
ment of donors and the processing and storage of faeces 
according to existing regulatory requirements or certification 
systems.
(5) Statement (EO): In the absence of other appropriate guid-
ance (eg, local directives), the scientific committee should estab-
lish protocols to direct the following duties: (a) evaluation and 
approval of requests from healthcare facilities; (b) regular review 
of the healthcare provider eligibility requirements; (c) regular 
analysis of stool bank activities; (d) analysis of reported adverse 
events (AEs).
Comment: FMT is not specifically regulated in all countries.21 
Local FMT programmes30 remain relatively rare worldwide. In 
the absence of dedicated local directives or direction from regu-
latory authorities, the scientific committee should be in charge of 
specific tasks, described in the statement.
(6) Statement (EO): Stool banks should undergo appropriate 
approval from the relevant national regulatory authorities of 
each country.
Comment: Some countries/regions regulate FMT as a drug, 
some as a tissue, some via ‘hybrid’ regulation, and others do 
not provide specific regulation. Specifically, the USA UK, and 
France regulate FMT as a medicinal product.31 The FDA has 
demonstrated evolution of their regulatory position on FMT 
over time, and exercise a policy of enforcement discretion 
regarding investigational new drug requirements where FMT is 
used for CDI not responding to standard treatment.32 In 2014, 
the European Commission expressed an opinion that FMT is 
a ‘combined product’, given the presence of both human cells 
and non-human components (eg, microbial genes) within the 
material; however, given that the human cellular components 
of FMT are not generally believed to be the active components, 
they have decided that FMT falls outside of the European Tissues 
and Cells Directives, and have deferred regulation to different 
European countries for national/local regulation.33 The Thera-
peutic Goods Administration in Australia are currently formu-
lating the regulatory framework for FMT in that country.34 
The expert panel agreed that all stool banks should continue 
to operate under the designated regulatory authority for each 
country.
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box 1 Key issues to select potential donors at the 
preliminary interview
Known history of, or risk factors for, infectious diseases
 ► History of HIV, hepatitis B or C viruses, syphilis, human 
T-lymphotropic virus I and II
 ► Current systemic infection
 ► Use of illegal drugs
 ► High-risk sexual behaviour
 ► Previous tissue/organ transplant
 ► Recent hospitalisation or discharge from long-term care 
facilities
 ► High-risk travel/engaged in medical tourism
 ► Recent (≤6 months) needle stick accident
 ► Recent (≤6 months) body tattoo, piercing, earring, 
acupuncture
 ► Recent (≤2 months) enteric pathogen infection
 ► Recent (≤2 months) acute gastroenteritis with or without 
confirmatory test
 ► History of receiving growth hormone, insulin from cows or 
clotting factor concentrates
 ► Recent (≤2 months) history of vaccination with a live 
attenuated virus, if there is a possible risk of transmission
disorders potentially associated with perturbation of the 
gut microbiota
 ► Personal history of chronic gastrointestinal disease, including 
functional gastrointestinal disorders; inflammatory bowel 
disease; coeliac disease; other chronic gastroenterological 
diseases
 ► Personal history of systemic autoimmune disorders
 ► Personal history of cancer, including gastrointestinal cancers 
or polyposis syndrome
 ► Recent abnormal gastrointestinal symptoms (eg, diarrhoea, 
haematochezia, etc)
 ► Personal history of neurological/neurodegenerative disorders
 ► Personal history of psychiatric/neurodevelopmental 
conditions
 ► Obesity (body mass index >30) and/or metabolic syndrome/
diabetes
 ► First-degree family history of premature colon cancer or first-
degree family history of early onset polyposis syndromes
drugs that can alter gut microbiota
 ► Recent (≤3 months) exposure to systemic antimicrobial 
drugs, immunosuppressant agents, chemotherapy
 ► Chronic treatment (≥3 months) with daily use of proton 
pump inhibitors
selection and screening of donors
(7) Statement (EO): Stool donation must be voluntary. Donors 
should be informed about the potential risks and benefits of 
donating and provide appropriate written informed consent.
Comment: Apart from the health screening, stool donors do 
not directly benefit from donating. Stool donation is signifi-
cantly different from other live tissue or cell-based donations 
as it is not invasive. Personnel recruiting donors should explain 
in detail the screening process and the measures taken to ensure 
donor confidentiality. Potential donors should be made aware 
that they can withdraw from this process at any time.35–38
(8) Statement (EO): Stool donors may receive financial 
compensation for their time and travel expenses or a reimburse-
ment that surpasses these expenses. Individual applicability of 
these concepts should follow local regulations.
Comment: There is longstanding debate about the provision 
of compensation for tissue or cell-based donors.39–41 In many 
regions (eg, Europe), direct compensation for tissue or cell-based 
donations is not permitted. In the USA, compensation for dona-
tion of some non-organ human material (eg, plasma or sperm) 
is permitted.
As compared with other types of donation, stool donation 
occurs much more frequently. Accordingly, there is a signif-
icant burden on stool donors, including logistical issues and 
restrictions on behaviour. Moreover, data from a large stool 
bank suggest high rates of donor drop out owing to major time 
commitments.42 The panel suggests that compensation and/or 
reimbursement may be provided if permitted by appropriate 
regulatory guidance.
(9) Statement: Recruitment of donors should be through a 
continuous, structured workflow to prevent shortages.
CoE: very low; SoR: weak
Comment: Among 330 physicians who did not offer FMT, 
80% reported difficulties with the logistics of preparation/
delivery, and 45% cited complexity and cost of donor screening 
as being prohibitive.43 Stool banks have emerged to facilitate 
access to FMT material as compared with patient-directed dona-
tion, but donor recruitment can be challenging. Observational 
data from a large stool bank suggest a high-rate of drop out and 
health-related exclusion from initial contact to stool donor qual-
ification.42 Others small academic stool banks from Australia, 
Canada, USA and Denmark have reported similar challenges in 
procuring healthy donors.28 44–47 Accordingly, we recommend 
dedicated donor operational personnel who use a structured 
workflow to ensure access to material.
(10) Statement: Undirected donors are recommended for stool 
bank recruitment. Under exceptional circumstances, patient-se-
lected donors may be used if both the patient and donor under-
stand the risks, benefits and alternatives.
CoE: low; SoR: strong
Comment: Evidence suggests that there is no significant 
difference in CDI cure rates between patient-selected and undi-
rected healthy donors.1–7 48 However, head-to-head randomised 
controlled trials (RCTs) comparing these two types of donors 
have not been conducted.
Patient-selected donors were more frequently used in early 
FMT studies. However, the use of healthy undirected donors 
is essential for a stool bank, and has significant advantages, 
including prevention of shortages, reduction of screening-re-
lated expenses, a higher traceability, and a reduced likelihood of 
confidentiality concerns.49
(11) Statement: The medical history of candidate donors has 
to be evaluated, at the beginning of the screening process, by a 
clinical questionnaire examining the risk of infectious diseases, 
the history of disorders potentially associated with perturbation 
of the gut microbiota and the use of treatments that can affect 
the gut microbiota (box 1).
CoE: moderate; SoR: strong
Comment: The purpose of the questionnaire is to minimise 
the risk of transferring infections or adverse gut microbiota 
‘traits’. When these or similar exclusion criteria are used, there 
have been few reported AEs related to the infusion of donor 
faeces.1–11
Since increasing age has been associated with altered gut micro-
biota composition, young individuals (aged <50 years or <60 if 
they have completed appropriate bowel cancer screening) are 
preferred as potential donors. Importantly, although the panel 
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box 2 donor blood and stool testing
blood testing
 ► Hepatitis A, hepatitis B, hepatitis C and hepatitis E viruses
 ► HIV-1 and HIV-2
 ► Treponema pallidum
 ► Nematodes (Strongyloides stercoralis)
 ► Complete blood cell count with differential
 ► Creatinine
 ► Aminotransferases, bilirubin
stool testing
 ► Clostridioides difficile
 ► Common enteric pathogens, including Salmonella, Shigella, 
Campylobacter, shiga toxin-producing Escherichia coli, 
Yersinia and Vibrio cholerae
 ► Antibiotic-resistant bacteria (ARB), including vancomycin-
resistant Enterococci, meticillin-resistant Staphylococcus 
aureus), Gram-negative ARB including extended-spectrum 
β-lactamase-producing Enterobacteriaceae, and carbapenem-
resistant Enterobacteriaceae/carbapenemase-producing 
Enterobacteriaceae
 ► Norovirus, rotavirus, adenovirus
 ► Giardia lamblia, Cryptosporidium spp, Isospora and 
Microsporidia
 ► Protozoa and helminths/va and parasites (including 
Blastocystis hominis and Dientamoeba fragilis)
 ► Helicobacter pylori faecal antigen (for upper route of FMT 
delivery)
recommends exclusion of candidates with a personal history of 
systemic autoimmune diseases, the evidence is insufficient to 
exclude donors with atopy, asthma or food/seasonal allergies. 
Additionally, the panel recommends excluding candidates with 
a personal history of cancer but would consider donors with a 
history of non-malignant skin cancers (eg, basal cell carcinoma) 
following appropriate treatment. Although some stool banks 
exclude healthcare workers with exposure to patients, available 
data suggest a low prevalence of antibiotic-resistant bacteria 
colonisation in this population.50 51
Overall, data from a large USA stool bank42 suggest that nearly 
90% of candidates are excluded after medical evaluation. Similar 
data have been presented by an Australian stool bank, where 
approximately 50% of donors are excluded after completion of 
the clinical questionnaire.44
(12) Statement: All candidate donors who have passed the 
medical interview must undergo blood and stool testing to 
exclude potentially transmittable diseases. Recommended tests 
are summarised in box 2.
CoE: moderate; SoR: strong
Comment: There is relevant heterogeneity of donor screening 
across FMT studies and screening tests were largely incomplete 
in >50% of published studies.52 The panel believes that it is 
indispensable to include a screening panel that should constitute 
a reference standard operating procedure (SOP) of stool banks.
Here the testing recommendations from the previous 
consensus report were updated.15 The panel recommends the use 
of validated standard of care test methods (eg, culture, ELISA, 
PCR, serology) according to nationally and locally approved 
guidelines. Given the low percentage of qualified donors42 and 
the mental effect of non-meaninful incidental findings among 
healthy donors, we recommend a pragmatic approach to testing.
For blood testing, cytomegalovirus (CMV) and Epstein-Barr 
virus (EBV) should be considered. However, there is a high prev-
alence of prior exposure to both viruses in many healthy adult 
donors, and there are no reported cases of CMV- or EBV-as-
sociated disease attributable to faecal transplants performed in 
FMT centres, even among immunocompromised individuals. 
Accordingly, the panel recommends that immunocompromised 
recipients at risk for CMV/EBV-associated disease must be tested 
for these viruses before undergoing FMT and, if seronegative, 
appropriate conversation about risk, benefits and alternatives 
(including patient-selected donor use) should be considered. 
Importantly, we do not recommend exclusion of donors who 
are either CMV and/or EBV IgG positive. Consideration may be 
given to testing for active CMV (IgM) as an alternative approach.
The panel also recommends that Strongyloides stercoralis 
should always be tested for but that other nematodes (eg, Ascaris 
lumbricoides, Taenia solium and Taenia hominis) could be 
considered for testing, based on the physician’s decision consis-
tent with clinical, social and geographical features of the donors.
C-reactive protein may be considered in blood testing as it 
may be useful for identifying an underlying inflammatory state. 
However it is a non-specific inflammatory marker and its use 
in healthy, asymptomatic individuals is limited and potentially 
prone to incidental findings.
Consideration of stool testing for astrovirus and sapovirus may 
be considered, though there is a paucity of data on its clinical 
usefulness in healthy, asymptomatic donors. Additionally, faecal 
calprotectin may be considered: high calprotectin levels may be 
important if clinical symptoms are present, although its useful-
ness in healthy asymptomatic adults remains unknown. Finally, 
recommendations from the recent FDA alert,20 about screening 
and testing of stool donors for multidrug-resistant organisms, 
have been incorporated in this statement (box 2).
(13) Statement: Donors should be given a questionnaire on 
the day of the donation to assess for any change in health that 
might have occurred since screening (box 3).
CoE: moderate; SoR: strong
Comment: To optimise safety and minimise risk, the panel 
recommends that donors complete a written questionnaire to 
assess for interval health change at each donation. This should 
include new symptoms, new sexual partners, high-risk travel and 
use of antibiotics or other drugs that might impair gut micro-
biota. This recommendation is supported by excellent safety 
data from several RCTs1–6 and meta-analyses.7–11
(14) Statement: Donors who repeatedly donate should 
undergo clinical assessment and a complete panel of laboratory 
testing every 8–12 weeks.
CoE: very low; SoR: weak
Comment: As with other cell and tissue donation, it is 
important to ensure the continued safety of donated material 
even after the initial testing and approval of the donor. Faeces can 
theoretically be donated daily, and repeating a complete blood 
and stool screening at each donation would be unreasonable.
The panel proposed several measures to guarantee the safety 
of donor faeces. After initial testing, each donated faecal aliquot 
should be either (1) directly tested with a rapid molecular assay 
for stool pathogens or (2) remain in quarantine until that donor 
has passed a further donor screening at the end of a period of 
donation (even if the donor does not wish to provide faeces any 
more), and be available for administration to patients only after 
this further check.
(15) Statement (EO): Before starting the screening process, 
candidate donors should sign a written informed consent 
form including (a) acceptance of the screening process; (b) a 
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box 3 Issues to deal with on the same day of donation 
to check for any recent-onset harmful events
 ► New GI signs and/or symptoms (eg, diarrhoea, nausea, 
vomiting, abdominal pain, jaundice)
 ► New infection signs and/or symptoms (eg, fever or swollen 
lymph nodes)
 ► Use of antimicrobial agents or other drugs that might impair 
gut microbiota since the last screening
 ► Unprotected sexual encounters with new partners since the 
last screening
 ► High-risk or tropical travel or direct contact with human 
blood since the last screening
box 4 General steps to be followed for the preparation 
of frozen faecal suspensions
 ► A minimum quantity of 25 g of faeces for lower 
gastrointestinal delivery and 12.5 g of faeces for upper 
gastrointestinal delivery should be used for each sample.
 ► Before freezing, a cryoprotectant (eg, glycerol) should 
preferably be added up to a final concentration of 10%.
 ► The final product must be put in a special sterile container, 
labelled, registered and stored at –80°C.
 ► On the day of faecal infusion, the faecal suspension 
should be thawed in a warm (37°C) water bath or at room 
temperature, and infused within 6 hours from thawing.
commitment to provide honest answers; (c) awareness that 
incorrect and/or dishonest answers might result in harm to recip-
ients; (d) a commitment to inform stool bank personnel imme-
diately if they become ill or have lifestyle changes that might 
affect suitability to donate; (e) a commitment to aim to provide 
multiple stool samples; (f) permission to have their data stored 
in a donor registry; (g) permission to store their samples and test 
them if serious AEs occur.
Comment: Donors should acknowledge the responsibilities 
and tasks associated with stool donation, including the risk of 
false-positive or incidental findings. All signed consent forms 
must be stored for at least 10 years, or in accordance with guide-
lines from local or national regulators.
Collection, preparation and storage of faeces
(16) Statement (EO): Faeces should preferably be collected on 
site at the stool bank in a specific single-use container. Where 
this is not possible, collected faeces should be cooled to 4°C and 
brought (preferably within 6 hours) to the stool bank, where 
they are accepted, identified, weighed, assessed for abnormali-
ties (eg, melaena, haematochezia), registered and processed by 
referring personnel.
Comment: Clear instructions should be given to donors about 
hand hygiene. Faeces should be transported to the stool bank as 
soon as possible after defaecation, to ensure that manipulation 
and storage is done within 6 hours.53 If a short period of storage 
is necessary, this should be at 4°C (±2°C) or at a colder tempera-
ture (but not freezing as repeated freeze–thawing cycles may 
affect the quality), as already described in a RCT,2 and recom-
mended by other guidelines.14
(17) Statement (EO): The receptacle containing faeces should 
have a reliable method of identification and traceability that 
bears the unique code of the donor and the date of collection 
and processing.
Comment: To provide efficient donor–recipient traceback, 
each faecal sample should be labelled with a unique bar code to 
enable full batch traceability.22
(18) Statement (EO): Stool banks must have facilities (at least 
biosafety level 2) adopting SOPs that allow safe processing of 
human samples in accordance with national or international 
regulations and requirements.
Comment: In our previous consensus report,15 we stated that 
high-quality microbiological facilities are needed to build a FMT 
centre. Here the panel suggests that the same strict requirements 
are needed also to develop a stool bank.54–56 Manipulation and 
storage of faeces must adhere to basic principles for safe prepa-
ration of human material, including strict working protocols 
to secure materials; maintenance of SOPs for the processing 
of stool; ongoing certified laboratory testing; determination 
of quality control tests; and standards for release of the final 
product.
(19) Statement: General steps for the preparation and storage 
of frozen faecal suspensions must be followed (box 4). The 
formulation of faecal suspensions should be set up for specific 
delivery routes, based on local expertise, clinician and patient 
preference.
CoE: moderate; SoR: strong
Comment: The manipulation of donor faeces into frozen 
suspensions is an essential step in the workflow of the stool 
bank. A head-to-head RCT has shown similar efficacy of frozen 
and fresh FMT for the treatment of CDI.2
The suggested steps were slightly amended from our previous 
report.15 As FMT can be administered through different routes 
and each centre may have different expertise and confidence 
with them, the stool bank should be able to provide faecal 
suspensions in adequate formulations for each route requested 
by the recipient centres. The minimum quantity of donor faeces 
for lower gastrointestinal delivery has been decreased from 
30 g to 25 g, and 12.5 g for upper gastrointestinal delivery, as 
these quantities have documented success in large stool banks.57 
Where upper gastrointestinal administration is considered most 
appropriate, both low-volume (30 mL)57 and high-volume 
(500 mL)58 preparations have been used, but there is still uncer-
tainly about the ideal dose; caution is recommended owing to 
the reported risk of regurgitation and aspiration pneumonia with 
higher volumes.58 Capsule preparations should follow standard 
protocol.6 Further evidence on optimal dosing and formulation 
of capsules is required.
Finally, The −80°C freezing temperature of the suspension 
and the use of glycerol as microbial cryopreservant have been 
used with success59 60 and were confirmed from our previous 
consensus.15
(20) Statement (EO): Containers of faecal suspensions 
should have a legible and indelible label that bears the unique 
code of the donor and the date of collection and processing. 
The code should be recorded in the recipient record/proce-
dure report.
Comment: Faecal suspensions, in combination with a small 
portion of the original faeces or a small (~2 mL) portion of the 
faecal suspension, must be stored under a unique donor code 
with a successive suffix number for donation time and date 
for retrospective quality assessment. Information on faecal 
suspension labels must include donor code, suspension number, 
production and expiration date, volume and storage tempera-
ture instructions.
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(21) Statement (EO): Stool banks should guarantee that all 
storage processes are carried out under controlled conditions 
and according to local, regional and national regulations.
Comment: Storage of faecal suspensions should be accom-
modated within the certified centralised biobanking facility in 
a specific −80°C freezer with connected alarm notification to 
ensure storage of the material at appropriate temperature. The 
temperature range of the stored material and the duration of any 
out-of-range periods must be recorded and controlled. Products 
that are exposed to temperature excursions, which might affect 
the quality of the final product, must be discarded according to 
local, national and international procedures for the management 
of medical waste.
(22) Statement: The faecal suspension can be stored or up to 
2 years. After this deadline, unused stored material must must be 
discarded according to local, national and international proce-
dures for the management of medical waste.
CoE: very low ; SoR: weak
Comment: Reports from a large stool bank show that the use 
of faecal suspensions stored for up to 2 years does not under-
mine the clinical success of FMT for the treatment of CDI if 
samples are stored at −80°C.42 61 62 However, as a preclinical 
study reports a decline in microbial viability in frozen faeces 
after 9 months,63 the panel suggests it is preferable to use frozen 
samples within 1 year from donation.
services and clients
(23) Statement (EO): Access to stool bank should be provided to 
physicians caring for patients with CDI. It cannot be provided 
directly to patients.
Comment: FMT has well-described potential drawbacks and 
recognised unknowns about its use, including potential risks 
related to invasive administration, a theoretical possibility for 
transfer of infection and limited long-term safety data. Thus, 
the expert panel considered that every FMT delivery requires 
administration, documentation and appropriate follow-up that 
can only safely occur under the direction of a physician. Conse-
quently, the expert panel concluded that it was inappropriate for 
faecal suspensions to be provided directly to patients.
(24) Statement (EO): Recipient centres should satisfy a set 
of criteria to access stool bank services, including (a) public or 
private hospitals or nursing homes that have identified a quali-
fied physician with experience in the field of FMT; (b) documen-
tation of treatments carried out, including procedure reports, 
patient data, preparation, timing and administration of the mate-
rial coming from the stool bank, and safety and efficacy results; 
(c) the team of centre must have undergone training in FMT. 
Moreover, recipient centres should be instructed on recom-
mended FMT best practices, including thawing of faecal suspen-
sions, delivery modalities, informed consent and follow-up.
Comment: The panel agreed that FMT should be performed 
under the supervision of an appropriately trained physician and 
suggested that a physician with prior experience within special-
ties including, but not limited to, gastroenterology or infectious 
disease/medical microbiology might be suitable for overseeing 
the care of patients receiving FMT. However, endoscopy-deliv-
ered FMT should be performed only by trained endoscopists to 
reduce the risk of complications.
Although the use of FMT has become increasingly well estab-
lished for the treatment of CDI within many teaching hospitals 
and academic centres, the panel noted that many physicians 
working outside these centres (including in primary care) have 
more limited knowledge of this technique. Thus, the panel 
concluded that there was a clear role for stool banks to educate 
healthcare professionals about FMT.
No data on the learning curve in FMT are available, but the 
panel's opinion was that physicians should have been trained by 
performing at least 10 FMT procedures before being considered 
to be trained.
(25) Statement (EO): Faecal samples provided by the stool 
bank must be used in the recipient centre according to the same 
working rules followed by the stool bank itself, and cannot be 
transported, sold or given to other centres or individuals.
Comment: FMT is not regulated in all countries and there 
might not be regulatory body to certify the banking facility. 
Nevertheless, the panel agreed on the importance of the use 
of a standardised protocol for the final aspects of preparation 
and administration of faecal suspensions for all recipient centres 
served by the same stool bank.
(26) Statement (EO): Costs of FMT should be based on a 
business case and budget impact analysis and subsequently, reim-
bursed by health insurance, which will vary from country to 
country.
Comment: In the context of CDI, FMT has consistently been 
shown to be cost-effective compared with other potential thera-
peutic options, even when evaluated in a variety of global health-
care settings.64 Nevertheless, in most cases funding of FMT 
services has been historically provided ad hoc by teaching hospi-
tals/academic centres, and FMT services sometimes run with a 
financial deficit.65 66 For sustainability of stool banks, the panel 
agreed that a robust business case and budget impact analysis is 
required.
(27) Statement (EO): Stool banks should document the release 
of each aliquot for transport and its destination. Faecal suspen-
sions should remain frozen during transport, typically by the 
use of dry ice. On arrival, the recipient centre should confirm 
and document the identity of each faecal sample and that it has 
remained frozen.
Comment: The material should remain frozen in transit, to 
minimise any potential perturbation of microbiota composition 
and/or functionality. A growing body of evidence demonstrates 
that length and temperature of storage of faecal suspensions 
and/or stool itself could influence the culturable microbiota 
and profiles of bacterially derived metabolites that have been 
associated with the efficacy of FMT, including short-chain fatty 
acids.54 67 68
(28) Statement: Unless the frozen faecal suspension is to be 
used imminently by the recipient centre, it should be transferred 
immediately to a freezer and kept for no more than 2 months at 
−20°C or for 2 years at −80°C or colder.
CoE: very low; SoR: weak
Comment: There are few data demonstrating that the storage 
temperature of faeces influences the composition and potential 
functionality of the microbiota.54 67 68 The expert panel noted 
that many recipient centres may not have routine access to 
−80°C freezers, and that a pragmatic, simple storage protocol 
for recipient centres is likely to increase accessibility and take-
up. Storage of faecal suspensions at −20°C for up to 30 days 
appeared not to reduce efficacy of FMT in the treatment of 
CDI compared with fresh material2; conversely, the Firmicutes/
Bacteroidetes ratio was significantly higher in faecal samples that 
had been frozen for more than 50 days compared with identical 
fresh samples.69 Collectively, based on expert opinion, faecal 
suspensions could safely be kept at −20°C (or colder) for up to 
2 months in freezers at recipient centres.14
(29) Statement (EO): Clear traceability should be present at all 
steps of the FMT supply chain (eg, by batch number labelling) 
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from the take-up of donated faecal samples through transport 
and delivery to sites and patient administration.
Comment: Recipient centres should retain thorough records 
of all steps of the supply chain, from the stool bank through to 
the point of patient administration, on the grounds of robust 
clinical governance. In the case of infectious AEs, this would 
facilitate a ‘look-back’ exercise from samples/records at the stool 
bank to identify if the donor was the source of the infection.61
registries, monitoring of outcomes and ethical issues
(30) Statement (EO): An aliquot of each stool donation should 
be kept frozen for future testing in the case of AEs, in keeping 
with regulatory guidance. If for any reason a stool bank ceases 
its activity, stored samples and related data will be transferred 
to another stool bank or bio-bank having the same rules and the 
donor will be notified of the change in placement. In the absence 
of this possibility, the sample will be discarded following rules 
governing disposal of biological waste.
Comment: Stool banks should store an aliquot of the donor 
faeces, or samples of all delivered faecal suspensions, to guar-
antee traceability in case of AEs.
(31) Statement (EO): Donor records, including results of the 
screening process and identities of donors, should be stored in an 
official registry according to local regulatory guidance.
Comment: Management of the records related to the FMT 
procedure should be regulated by local health authorities. FMT 
procedure and donors’ and recipients’ records should be stored 
for at least 10 years. This may differ according to local and 
national requirements, and longer storage time may be neces-
sary. The records of the stool bank will provide access to the 
long-term safety data.
(32) Statement: Practitioners of FMT should monitor patients 
for severe AEs that may be attributable to the procedure, such 
as hospitalisation, death or transmission of infections. These 
should be reported at the institutional level and to applicable 
regulatory agencies.
CoE: low; SoR: strong
Comment: The safety of FMT is one of the greatest concerns 
related to its use.70 71 Short-term AEs relate primarily to the 
method of delivery or to acute infections contracted from the 
donor. Severe AEs include the following: death; life-threatening 
event; hospitalisation; disability or permanent impairment; 
other important event, including serious infection transmission 
(eg, HIV or viral hepatitis). All AEs potentially related to FMT, 
excluding extremely minor ones (eg, transient constipation or 
bloating), should be registered.
(33) Statement (EO): Recipient registries may be useful to 
monitor FMT recipients for AEs.
Comment: The potential for long-term consequences of FMT 
is almost unknown. A priori knowledge is not available about the 
impact of transferring complex microbial communities. Animal 
studies have indicated that the composition of the gut microbiota 
can affect host susceptibility to diseases,72 and human studies 
have consistently shown that FMT durably alters the micro-
biome of the recipient.73 74 FMT is unlike other treatments in 
that it was rapidly adopted for widespread clinical use, bypassing 
the drug-development process, which typically collects prospec-
tive efficacy and safety data on large numbers of patients before 
making a treatment available.64 75 Therefore, it is important to 
collect real-world evidence for the short- and long-term safety 
of the procedure. In the USA and Europe, FMT recipient regis-
tries have been launched to track efficacy and safety outcomes 
in adult and paediatric patients after FMT.17 76 77 In addition to 
infections, the possibility that gut microbiota associated with 
a disease phenotype (eg, obesity) will be transplanted and the 
risk for these chronic disorders in recipients must be assessed. 
Prospective registries enrolling large cohorts of recipients with 
long-term follow-up are the only practical method to achieve 
this aim.78
evolving role of FMT in clinical practice
(34) Statement: FMT is highly recommended as a treatment 
option for multiply recurrent CDI
CoE: high; SoR: strong
Comment: FMT has a well-established role in the treatment 
of multiply recurrent CDI. This is typically defined as three or 
more confirmed episodes or two episodes that required hospital-
isation. It has been found to be better than the standard of care 
antibiotics and placebo in several RCTs.1–6 In addition, several 
meta-analyses suggest that FMT can achieve nearly 90% clinical 
cure rate for the treatment of recurrent CDI.7–11
(35) Statement: FMT is recommended as an option for severe 
CDI not responding to standard treatment.
CoE: moderate; SoR: strong
Comment: FMT has been shown to be an effective treat-
ment for patients with severe CDI not responding to standard 
of care antibiotics (according to pertinent guidelines), regard-
less of the number of previous episodes. In several randomised 
and non-randomised studies, sequential faecal infusion protocols 
were highly successful in patients with severe CDI.79–83
(36) Statement: FMT may be considered as a treatment option 
for fulminant CDI (defined as severe CDI plus hypotension or 
shock, ileus or toxic megacolon) in patients unfit for surgery.
CoE: very low; SoR: weak
Comment: Surgery is still considered the best option for 
patients with fulminant CDI not responding to maximum 
medical treatment. However, a subset of patients will be deemed 
unfit for surgery and in these cases, FMT can be considered as 
rescue therapy.79 80
(37) Statement: FMT could induce remission in mild-to-mod-
erate ulcerative colitis (UC). Other potential therapeutic targets 
for FMT beyond CDI include metabolic syndrome, irritable 
bowel syndrome, hepatic encephalopathy, gut decolonisation of 
multidrug-resistant organisms, primary sclerosing cholangitis, 
autism and various roles in cancer. However, further studies 
are required before FMT can be recommended as a treatment 
option for any of these indications in clinical practice. To date, 
its use should be limited to the research setting or compassionate 
use, in the absence of alternative therapeutic options.
CoE: moderate; SoR: weak
Comment: Increasing evidence suggests that FMT could be 
a treatment option in other disorders beyond CDI. The most 
robust data come from studies in UC, as RCTs and meta-anal-
yses show that FMT can induce clinical remission in nearly 30% 
of patients with mild-to-moderate UC,84–91 although data about 
maintenance of remission are still limited.92
The effect of FMT on irritable bowel syndrome has been 
investigated in several RCTs and in a meta-analysis, but the 
results are heterogeneous, and FMT cannot be recommended 
for this indication.93–96 Early evidence suggests that FMT might 
be a promising approach in hepatic encephalopathy,97 98 meta-
bolic syndrome,99 100 decolonisation of multidrug-resistant 
bacteria,101–103 primary sclerosing cholangitis,104 autism,105 and 
in the treatment of cancer.106 107 Nevertheless, many problems 
about the use of FMT in these non-CDI indications remain 
unresolved, including the identification, for each indication, 
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of successful donor profiles, adequate working protocols and 
correct integration of FMT within the therapeutic management 
pathway of the disease.
Owing to the increasing media attention around microbiome 
research, many patients are seeking FMT for a wide variety of 
non-CDI indications, though there is limited evidence for effi-
cacy in these. Physicians may feel pressured by these patients 
and unsure how to act, though the decision to recommend 
FMT should follow the same logic as the recommendation of 
any other medical treatment under development. In this situ-
ation, clinical trials offer the safest and most ethical treatment 
option.108 109 Related ethical issues should be discussed with 
patients. Those who do not have access to clinical trial partic-
ipation for a condition in which there is some likelihood that 
FMT may provide benefit, and in the absence of alternative 
therapeutic options or where all available standard treatments 
have failed, may be offered FMT as compassionate use after 
appropriate informed consent and approval from a local ethics 
committee.
(38) Statement: FMT is a safe and effective treatment for CDI 
in children.
CoE: low; SoR: strong
Comment: There is sufficient evidence to support the safety 
and efficacy of FMT in children with CDI.110 111 CDI presents 
a growing health concern in young patients who are also more 
likely to have community-acquired CDI. Children who do not 
respond to standard antibiotic treatment, or who have recurrent 
or severe CDI, may be candidates for, and benefit from, FMT.
(39) Statement: The safety of FMT during pregnancy is 
unknown, therefore it should be avoided unless strictly needed.
CoE: very low; SoR: weak
Comment: To date there is insufficient evidence to evaluate 
clearly the safety of FMT during pregnancy.112 However, FMT 
could be used as a rescue treatment in pregnant women with 
overwhelming CDI if standard medical treatments are ineffective.
(40) Statement: FMT is generally safe in the short term 
(<1 year), but plentiful data on long-term safety are still lacking. 
This fact should be discussed with patients and family and docu-
mented in the informed consent document.
CoE: low; SoR: weak
Comment: Some study including a small cohort of patients 
shows that FMT is safe at a 4-year follow-up,74 but plentiful 
follow-up FMT trial data are still lacking. Trials are underway to 
collect data over a 10-year follow-up period after FMT.113
ConClusIons
This consensus report provides guidance on the general organi-
sation and the criteria required to develop a stool bank. Several 
statements were presented as expert opinions and not following 
a GRADE approach owing to their intrinsically organisational or 
technical nature.
The expert panel identified roles and positions necessary to 
start stool banking activities, considered the issues of donation 
and donor recruitment/screening, and provided guidance on the 
preparation and storage of faeces. Guidelines on how to release 
faecal suspensions to centres and deal with safety and ethical 
concerns were established. Finally, in comparison with the previ-
ously published consensus conference,15 insufficient scientific 
evidence exists to support the use of FMT in clinical conditions 
other than the CDI, nor are data on long-term safety yet avail-
able. Despite the poor quality of evidence, a strong strength of 
recommendation is recognised in considering the option of FMT 
for treatment of children with CDI.
In conclusion, FMT should be accessible to all patients with 
CDI based on medical need with no interference from other 
factors, including site of hospitalisation, type of hospital or 
ability to pay. Given that the provision of FMT services is at 
present unequally distributed throughout certain countries,65 66 
a stool bank would guarantee the dissemination of FMT world-
wide and the accessibility of this potentially lifesaving procedure 
in an equitable fashion.
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